Extra scrutiny is warranted to identify the underlying causes of chest pain in patients with nonobstructive coronary disease ...

One month of dual antithrombotic therapy followed by direct oral anticoagulation alone may be as safe vs. 1 year of dual ...

New study shows a longer course of dual antithrombotic therapy may not be necessary for some patients with atrial ...

The PFA-SHAM trial and MANIFEST-US registry support the efficacy and safety of the increasingly used ablation modality.

Bristol Myers Squibb and Johnson & Johnson to discontinue phase 3 Librexia ACS trial of milvexian treat acute coronary syndrome: Princeton, New Jersey Monday, November 17, 2025, 1 ...

BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in ...

Internal medicine and rheumatology specialist Siobhan Deshauer, MD, looks at the signs of heart disease you can see.

Miami-based influencer Ben Bader’s cause of death has been revealed in an autopsy report after he died suddenly at 25, Us ...

Using real world data, researchers sought to compare outcomes in patients living in urban and non-urban communities who were treated for pulmonary embolism.

Background Percutaneous ventricular assist devices (pVAD) have been increasingly used to support haemodynamics during ...

For patients who have undergone successful catheter ablation for atrial fibrillation, treatment with rivaroxaban does not offer superior stroke protection versus aspirin.

Q: I’m only 45, but my doctor says that I need to focus on my heart health — make sure my cholesterol level remains healthy ...